In human, OCTN2 (SLC22A5) and ATB 0,+ (SLC6A14) transporters mediate the uptake of L-carnitine, essential for the transport of fatty acids into mitochondria and the subsequent degradation by β-oxidation. Aim of the present study is to characterize L-carnitine transport in EpiAirway™, a 3D organotypic in vitro model of primary human tracheal-bronchial epithelial cells that form a fully differentiated, pseudostratified columnar epithelium at air-liquid interface (ALI) condition. In parallel, Calu-3 monolayers grown at ALI were used as comparison. In EpiAirway™, ATB 0,+ was highly expressed and functional on the apical side while OCTN2 transporter was active on the basolateral side. Calu-3 cells showed a different pattern of expression and activity for ATB 0,+ :
INTRODUCTION
L-Carnitine (β-hydroxy-γ-trimethylaminobutyrate) is a small highly polar zwitterionic molecule essential in the transfer of activated long-chain fatty acids across the inner mitochondrial membrane in a series of reactions called the "carnitine shuttle", so that they can undergo degradation by β-oxidation [1] . Besides its key role in energy metabolism, several studies provide evidence that L-carnitine also functions as a cytoprotector by promoting cell resistance and antiapoptotic pathways, as well as by enhancing antioxidative resources [2, 3, 4] . In humans, the transport of L-carnitine across the cell membrane is mediated by OCTN1 (SLC22A4), OCTN2 (SLC22A5) and ATB 0,+ (SLC6A14).
OCTN2 operates a Na + -dependent, high-affinity (Km is in the range of 10-20 μM) transport of Lcarnitine, the physiological substrate, and other carnitine derivatives, as well as a Na + -independent transport of organic cations [5, 6] . In polarized epithelia such as intestine and kidney OCTN2 is located in the apical membrane of the cells [7] where it is involved in intestinal absorption and renal reabsorption. The transporter is also expressed in human macrophages, where it has been identified as a novel target gene of the mTOR-STAT3 axis [8] . Moreover, OCTN2 expression has been demonstrated in liver, heart, testis, skeletal muscle, lung and brain, sustaining a role for the transporter in the systemic distribution of carnitine [9] . The role of OCTN2 in the modulation of carnitine availability is clearly evidenced by the autosomal recessive disorder "Systemic primary carnitine deficiency" (SPCD; OMIM 212140) in which OCTN2 mutations strongly compromise the function of several tissues [1] and lead to severe clinical signs, such as respiratory insufficiency, vomiting, progressive cardiomyopathy, skeletal myopathy, hypoglycemia, and hyperammonemia.
Due to the genetic defect, dietary L-carnitine is poorly absorbed in the intestinal tract and lost in the urines because of the defective renal reabsorption from the glomerular filtrate; this reduces circulating carnitine levels and decreases intracellular carnitine accumulation with consequent impairment of fatty acid oxidation.
Contrary to OCTN2, the physiological role of OCTN1 is thus far not unequivocally defined. The transporter, specific for ergothioneine [10] , is endowed with a only low affinity for L-carnitine.
However, the group of Longo N. demonstrated some years ago that the expression of human OCTN1 in transfected CHO (Chinese Hamster Ovary) cells fails to cause any significant increase in L-carnitine transport [11] ; similarly, we recently demonstrated that, despite its expression in human bronchial A549 and BEAS-2B cells, OCTN1 in not involved in carnitine transport in these models [8] .
The other transporter involved in carnitine absorption is ATB 0,+ , a system responsible for the Na + /Cl --dependent influx of neutral and cationic amino acids. This transporter has a low affinity (Km = 800 μM) for L-carnitine, but an high concentrative capacity, being energized by the transmembrane gradients of Na + and Cl − , as well as by membrane potential [12] . Consistent with functional studies, ATB 0,+ is expressed in the lung and intestine under normal conditions [13, 14] where it is supposed to be mainly involved in nutrient uptake, due to its broad specificity and concentrative transport mechanisms [15, 16] .
In our previous study we performed a characterization of L-carnitine transport in different human airway epithelial models (A549, Calu-3, NCl-H441, and BEAS-2B), demonstrating that OCTN2 is the only L-carnitine transporter in A549 and BEAS-2B cells, while both OCTN2 and ATB 0,+ are operative in Calu-3 and NCl-H441 [17] . It is noteworthy, however, that these models are immortalized or transformed cell lines and criticisms exist as their biological functions can differ from those of primary differentiated human airway epithelial cells; moreover, the biological features of these cells may be modified under culture conditions and, in particular for Calu-3, evidences established a clear dependence on culture time and passage number for optimal barrier integrity, mucous secretion, and P-gp expression [18] .
The purpose of the present study is, hence, to characterize L-carnitine transport in an in vitro model of normal human respiratory cells; to this end, EpiAirway™ a 3D organotypic model of human mucociliary airway epithelium consisting of normal, human-derived differentiated tracheal/bronchial epithelial cells, has been employed and compared with Calu-3 cells grown under air-liquid interface (ALI) condition.
METHODS

EpiAirway™ primary cultures.
EpiAirway™ tissues (AIR-200-PE6.5), supplied by MatTek Corporation (Ashland, MA), were used.
Cultured on microporous membrane inserts at the air-liquid interface (ALI), EpiAirway™ tissues recapitulates aspects of the in vivo microenvironment of the lung [19, 20] ; this system is, indeed, produced from primary human tracheal-bronchial epithelial cells that form a fully differentiated, pseudostratified columnar epithelium containing mucus-producing goblet cells, ciliated cells and basal cells. Upon arrival, tissue inserts were transferred to 24-well plates containing 600 µl of the AIR 200-M125 medium and equilibrated overnight at 37°C and 5% CO 2 ; medium at the basolateral side was, then, renewed every day, while apical washes for mucus removal were performed employing the solution provided by the manufacturer. Cultures from four different healthy donors were employed.
Calu-3 cell line.
Calu-3 cells (American Type Culture Collection), obtained from a human lung adenocarcinoma and derived from serous cells of proximal bronchial airways, were cultured in Eagle's Minimum Essential Medium (EMEM) supplemented 10% fetal bovine serum (FBS), sodium pyruvate (1 mM) and 1% penicillin/streptomycin. Cells between passages 25-30 were routinely cultured under physiological conditions (37.5 °C, 5% CO 2 , 95% humidity) in 10-cm diameter dishes. For the experiments, Calu-3 cell monolayers were grown at air-liquid interface (ALI). To this end, cells were seeded onto Transwell polyester inserts (0.33 cm 2 , 0.4 µm pore size; Falcon) at the density of 10 5 cells/insert; the apical medium was removed 24 hours after seeding, while basolateral medium was renewed every other day. The monolayers were allowed to differentiate under ALI condition over 8 or 21 days.
Carnitine uptake.
Carnitine transport was measured both at apical and at the basolateral side. After two washes in pre-warmed transport buffer (Earle's Balanced Salt Solution (EBSS) containing (in mM) 117 NaCl, 1.8 CaCl 2 , 5.3 KCl, 0.9 NaH 2 PO 4 , 0.8 MgSO 4 , 5.5 glucose, 26 Tris/HCl, adjusted to pH 7.4), cells were incubated in fresh transport buffer (100 µl apical and 600 µl basolateral) containing L-[ 3 H]carnitine (2 μCi/ml). For a sodium-free EBSS, 117 mM NaCl was replaced with equimolar N-methyl-Dglucamine chloride. Where indicated, the inhibitors were added to the transport buffer at the indicated concentrations. After 30 min, transport buffer was removed, and the experiment terminated by two rapid washes (< 10 s) in ice-cold 300 mM urea. The filter was, then, detached from the insert and the ethanol soluble pool was extracted from monolayers; radioactivity in cell extracts was determined with MicroBeta2 liquid scintillation spectrometer (Perkin Elmer, Italy). Protein content in monolayers was determined directly in the filters using a modified Lowry procedure [21] . L-carnitine uptake is expressed as pmol/mg of protein, as indicated. In order to discriminate the contribution of OCTN2 and ATB 0,+ transporters, carnitine transport was measured either in the absence or in the presence of betaine or arginine employed as inhibitors of OCTN2 and ATB 0,+ , respectively [17] . Hence, the activity of ATB 0,+ is calculated from the difference between total transport and that measured in the presence of arginine, while the activity of OCTN2 results from the difference between total transport and that measured in the presence of betaine.
RT-qPCR analysis
Total RNA was isolated with GeneJET RNA Purification Kit and reverse transcribed with RevertAid 
Statistical analysis
GraphPad Prism 7 (GraphPad Software, San Diego, CA, US) was used for statistical analysis. P values were calculated with a two tailed Student's t-test for unpaired data; p < 0.05 was considered significant.
Materials
Fetal bovine serum was purchased from EuroClone (Milano, Italy). Carnitine-L-[N-methyl-3 H]HCl (80 Ci/mmol) was obtained from Perkin-Elmer (Milano, Italy). Sigma-Aldrich (Milano, Italy) was the source of the antibodies against ATB 0,+ and, unless otherwise specified, of all other chemicals.
RESULTS
In order to address the specific transporters involved in L-carnitine uptake in EpiAirway™ cells, 30-min uptake of 1 µM carnitine was performed at both apical and basolateral side in the absence and in the presence of sodium and in the presence of specific transporters inhibitors (Figure 1 ).
Carnitine influx was totally sodium-dependent at both culture sides, being the transport almost completely suppressed in the absence of the cation. On the apical compartment, L-carnitine uptake was fully inhibited by arginine, which share with carnitine ATB 0,+ transporter, while betaine, substrate of OCTN2, was completely ineffective. Otherwise, at basolateral side, while betaine markedly inhibited carnitine transport, arginine was completely ineffective. Overall, these findings indicate that L-carnitine transport in EpiAirway™ cell system is mediated by ATB 0,+ transporter on the apical side and by OCTN2 in the basolateral side. In this study the functional activity of ATB 0,+ and OCTN2 transporters in EpiAirway ™ was compared with that of Calu-3 monolayers, one of the reference model in the studies of transporter proteins and drug absorption [23] . In EpiAirway™, the functional analysis of the transport of L-carnitine, substrate of both ATB 0,+ and OCTN2, revealed that ATB 0,+ is present at apical level while OCTN2 at the basolateral side. As far as ATB 0,+ is concerned, data of transport analysis are fully in agreement with the immunocytochemical staining which showed a strong positivity of the protein at plasma membrane at the apical side. As far as the biologiocal role of this transporteer, it has been suggested that ATB 0,+ is expressed at places where the body interfaces with microbes, such as lung and colon and it may be involved in reducing available nutrients to bacteria [14] . Accordingly, the transporter is upregulated in inflammatory states, such as ulcerative colitis, Crohn's disease and colon cancer [14] . Moreover, genome-wide association studies has been recently identified ATB 0,+ (SLC6A14) as a genetic modifier of lung disease severity in cystic fibrosis, providing a mechanism by which it regulates Pseudomonas aeruginosa attachment to human bronchial epithelial cells [24] . Compared to Calu-3 monolayers, a close similarity between the two cell models is observed only when Calu-3 layers are maintained at ALI for 8 days. Indeed, the uptake of carnitine through ATB 0,+ as well as its expression, are no longer appreciable when the cultures of Calu-3 cells are prolonged to 21 days, when the monolayers are fully differentiated. This finding, hence, confirms that the biological features of these cells may be modified by the culture conditions, and includes the expression of ATB 0,+ to the list of parameters that vary along with the duration of the culture. As far as OCTN2 expression, here we show that carnitine transport through OCTN2 is similar in EpiAirway™ and Calu-3 where it appears localized on the basolateral membranes of both cell models. Our functional data are not in accordance with an immunohistochemistry analysis recently performed in lung tissues from healthy and COPD patients [25] : in this study, indeed, OCTN2 is founded on the apical and lateral side of the epithelial cells in the bronchial region and in cells lining the bronchioles. Since our findings do not highlight any transport activity through OCTN2 at the apical side, further investigations are necessary to ascertain the discrepancy between the positivity of immunohystochemical staining and the actual functional activity.
Beyond transporting L-carnitine, ATB 0,+ and OCTN2 have significant potential as delivery systems for amino acid-based drugs and prodrugs [13, 26] ; OCTN2 in particular interacts with inhaled drugs e.g. muscarinic antagonists and β-adrenergic agonists cationic bronchodilators [27] ; moreover, this transporter offer an efficient means to deliver drug or drug-loaded nanoparticles conjugated to carnitine [28] . Overall, the identification of the ATB 0,+ and OCTN2 transporters in the EpiAirway™ can open new fields of investigation in the studies of drug inhalation and pulmonary delivery.
CONCLUSIONS
In conclusion, in EpiAirway™ cells carnitine is transported through ATB 0,+ transporter at apical side and OCTN2 transporter at the basolateral side. A similar pattern of transporters is present only in Calu-3 monolayers cultured at ALI condition for short time; indeed when the culture was prolonged for 21 d, the activity of ATB 0,+ was no more detectable.
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